WO2005044853A3 - Anti-vegf antibodies - Google Patents

Anti-vegf antibodies Download PDF

Info

Publication number
WO2005044853A3
WO2005044853A3 PCT/US2004/029332 US2004029332W WO2005044853A3 WO 2005044853 A3 WO2005044853 A3 WO 2005044853A3 US 2004029332 W US2004029332 W US 2004029332W WO 2005044853 A3 WO2005044853 A3 WO 2005044853A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf antibodies
vegf
antibodies
binding
variants
Prior art date
Application number
PCT/US2004/029332
Other languages
French (fr)
Other versions
WO2005044853A2 (en
Inventor
Germaine Fuh
Hanspeter Gerber
Wei-Ching Liang
Frederic A Fellouse
Sachdev S Sidhu
Christian Wiesmann
Original Assignee
Genentech Inc
Germaine Fuh
Hanspeter Gerber
Wei-Ching Liang
Frederic A Fellouse
Sachdev S Sidhu
Christian Wiesmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/024662 external-priority patent/WO2005012359A2/en
Application filed by Genentech Inc, Germaine Fuh, Hanspeter Gerber, Wei-Ching Liang, Frederic A Fellouse, Sachdev S Sidhu, Christian Wiesmann filed Critical Genentech Inc
Publication of WO2005044853A2 publication Critical patent/WO2005044853A2/en
Publication of WO2005044853A3 publication Critical patent/WO2005044853A3/en
Priority to US11/414,742 priority Critical patent/US7758859B2/en
Priority to US12/816,188 priority patent/US8512699B2/en
Priority to US13/929,338 priority patent/US8975381B2/en
Priority to US14/603,693 priority patent/US20150175689A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
PCT/US2004/029332 2003-08-01 2004-09-08 Anti-vegf antibodies WO2005044853A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11/414,742 US7758859B2 (en) 2003-08-01 2006-04-27 Anti-VEGF antibodies
US12/816,188 US8512699B2 (en) 2003-08-01 2010-06-15 Anti-VEGF antibodies
US13/929,338 US8975381B2 (en) 2003-08-01 2013-06-27 Anti-VEGF antibodies
US14/603,693 US20150175689A1 (en) 2003-08-01 2015-01-23 Anti-vegf antibodies

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US51649503P 2003-11-01 2003-11-01
US60/516,495 2003-11-01
US57091204P 2004-05-12 2004-05-12
US60/570,912 2004-05-12
US57123904P 2004-05-13 2004-05-13
US60/571,239 2004-05-13
US57631504P 2004-06-01 2004-06-01
US60/576,315 2004-06-01
US58075704P 2004-06-18 2004-06-18
US60/580,757 2004-06-18
PCT/US2004/024662 WO2005012359A2 (en) 2003-08-01 2004-07-30 Anti-vegf antibodies
USPCT/US2004/024662 2004-07-30

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2004/024662 Continuation-In-Part WO2005012359A2 (en) 2003-08-01 2004-07-30 Anti-vegf antibodies
US11/342,249 Continuation-In-Part US7811785B2 (en) 2003-08-01 2006-01-27 Anti-VEGF antibodies

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2004/024662 Continuation WO2005012359A2 (en) 2003-08-01 2004-07-30 Anti-vegf antibodies
US11/342,249 Continuation-In-Part US7811785B2 (en) 2003-08-01 2006-01-27 Anti-VEGF antibodies
US11/414,742 Continuation US7758859B2 (en) 2003-08-01 2006-04-27 Anti-VEGF antibodies

Publications (2)

Publication Number Publication Date
WO2005044853A2 WO2005044853A2 (en) 2005-05-19
WO2005044853A3 true WO2005044853A3 (en) 2006-01-05

Family

ID=34577974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/029332 WO2005044853A2 (en) 2003-08-01 2004-09-08 Anti-vegf antibodies

Country Status (1)

Country Link
WO (1) WO2005044853A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8674083B2 (en) 1999-01-15 2014-03-18 Genentech, Inc. Polypeptide variants with altered effector function
US9266948B2 (en) 2009-12-23 2016-02-23 Genentech, Inc. Anti-Bv8 antibodies and uses thereof
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
JP7227151B2 (en) 2017-03-22 2023-02-21 ジェネンテック， インコーポレイテッド Antibody Compositions Optimized for Treatment of Eye Disorders

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
EP2322554A1 (en) * 2004-06-30 2011-05-18 Domantis Limited Composition comprising an anti-TNF-alpha domain antibody for the treatment of rheumatoid arthritis
BRPI0513534A (en) 2004-07-20 2008-05-06 Genentech Inc angiopoietin-like protein 4 inhibitors, combinations, and their use
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
RS52539B (en) 2004-10-21 2013-04-30 Genentech Inc. Method for treating intraocular neovascular diseases
SG165322A1 (en) 2005-08-31 2010-10-28 Schering Corp Engineered anti-il-23 antibodies
BRPI0709338A2 (en) 2006-03-21 2011-07-12 Genentech Inc antibody, isolated nucleic acid molecule, cell, compositions, alpha5beta1 protein detection method, antibody use, treatment methods, kit, use of a composition, use of an alpha5beta antagonist, and use of a vegf antagonist
CN101448856A (en) * 2006-03-29 2009-06-03 健泰科生物技术公司 Diagnostics and treatments for tumors
JP2009539384A (en) 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド Anti-DLL4 antibody and method of using anti-DLL4 antibody
EP2129690A1 (en) 2006-12-14 2009-12-09 Schering Corporation Engineered anti-tslp antibody
AU2014201795B2 (en) * 2006-12-19 2016-05-19 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
AR065271A1 (en) 2007-02-09 2009-05-27 Genentech Inc ANTI-ROBO4 ANTIBODIES AND THEIR USES
PL2426144T3 (en) 2007-02-23 2019-05-31 Merck Sharp & Dohme Engineered anti-il-23p19 antibodies
EP2426145B1 (en) 2007-02-23 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23p19 antibodies
EP2395025A1 (en) 2007-02-28 2011-12-14 Schering Corporation Engineered Anti-IL-23R Antibodies
ES2554812T3 (en) 2007-11-09 2015-12-23 Genentech, Inc. Activin receptor-type kinase 1 antagonist compositions and methods of use
TWI468417B (en) 2007-11-30 2015-01-11 Genentech Inc Anti-vegf antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
UY31861A (en) 2008-06-03 2010-01-05 Abbott Lab IMMUNOGLOBULIN WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab Dual variable domain immunoglobulins and uses thereof
DK3216803T3 (en) * 2008-06-25 2020-06-02 Novartis Ag Stable and soluble antibodies that inhibit vegf
WO2010006060A2 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
WO2010010153A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Identification of subjects being susceptible to anti-angiogenesis therapy
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JP5913980B2 (en) 2008-10-14 2016-05-11 ジェネンテック， インコーポレイテッド Immunoglobulin variants and uses thereof
WO2010059969A2 (en) 2008-11-22 2010-05-27 Genentech, Inc. Anti-angiogenesis therapy for the treatment of breast cancer
MX2011010012A (en) 2009-03-25 2011-12-06 Genentech Inc Novel anti-î+-5î²1 antibodies and uses thereof.
PL2417156T3 (en) 2009-04-07 2015-07-31 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
AR077595A1 (en) 2009-07-27 2011-09-07 Genentech Inc COMBINATION TREATMENTS
MX2012001716A (en) 2009-08-14 2012-04-02 Genentech Inc Biological markers for monitoring patient response to vegf antagonists.
TW201431558A (en) 2009-08-15 2014-08-16 建南德克公司 Anti-angiogenesis therapy for the treatment of previously treated breast cancer
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
CA2773662A1 (en) 2009-09-11 2011-03-17 Genentech, Inc. Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
CA2772670A1 (en) 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
MX2012009554A (en) 2010-02-23 2012-11-23 Hoffmann La Roche Anti-angiogenesis therapy for the treatment of ovarian cancer.
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
AR080794A1 (en) 2010-03-26 2012-05-09 Hoffmann La Roche BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
MX2013000672A (en) 2010-07-19 2013-02-27 Hoffmann La Roche Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy.
MX2013000667A (en) 2010-07-19 2013-02-27 Hoffmann La Roche Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy.
JP2013537415A (en) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド Dual variable domain immunoglobulins and uses thereof
MX340558B (en) 2010-08-24 2016-07-14 F Hoffmann-La Roche Ag * Bispecific antibodies comprising a disulfide stabilized - fv fragment.
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
SG190788A1 (en) 2010-11-15 2013-07-31 Five Prime Therapeutics Inc Fgfr1 extracellular domain combination therapies
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
KR101638224B1 (en) 2011-02-28 2016-07-08 에프. 호프만-라 로슈 아게 Antigen binding proteins
CN103403025B (en) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 Monovalent antigen binding protein
HUE041335T2 (en) 2011-03-29 2019-05-28 Roche Glycart Ag Antibody fc variants
SG194045A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and abiraterone, and methods of use
AU2012245439B2 (en) 2011-04-20 2017-04-06 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
EP2744825A1 (en) 2011-08-17 2014-06-25 F.Hoffmann-La Roche Ag Inhibition of angiogenesis in refractory tumors
CA2856873A1 (en) 2011-11-23 2013-05-30 Igenica, Inc. Anti-cd98 antibodies and methods of use thereof
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
EP2793941A1 (en) 2011-12-23 2014-10-29 F.Hoffmann-La Roche Ag Articles of manufacture and methods for co-administration of antibodies
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
RU2659173C2 (en) 2012-01-13 2018-06-28 Дженентек, Инк. Biological markers for identifying patients for treatment with vegf antagonists
KR20140127854A (en) 2012-02-10 2014-11-04 제넨테크, 인크. Single-chain antibodies and other heteromultimers
SI2825558T1 (en) 2012-03-13 2019-08-30 F. Hoffmann-La Roche Ag Combination therapy for the treatment of ovarian cancer
CA2867588A1 (en) 2012-03-30 2013-10-03 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
AR091220A1 (en) 2012-05-31 2015-01-21 Genentech Inc METHODS TO TREAT CANCER USING ANTAGONISTS OF UNION TO PD-1 AXIS AND ANTIGONISTS OF VEGF
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
RU2639287C2 (en) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Method for selection and obtaining of highly selective and multispecific targeting groups with specified properties, including at least two different binding groups, and their applications
PE20150361A1 (en) 2012-07-13 2015-03-14 Roche Glycart Ag ANTI-VEGF / ANTI-ANG-2 BISPECIFIC ANTIBODIES AND THEIR USE IN THE TREATMENT OF EYE VASCULAR DISEASES
JP6464085B2 (en) 2012-08-07 2019-02-06 ジェネンテック， インコーポレイテッド Combination therapy for the treatment of glioblastoma
AU2013329311A1 (en) 2012-10-09 2015-04-30 Igenica Biotherapeutics, Inc. Anti-C16orf54 antibodies and methods of use thereof
NZ707641A (en) 2012-11-01 2016-09-30 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
US20140154255A1 (en) * 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
TW201512219A (en) 2013-03-15 2015-04-01 Abbvie Inc Dual specific binding proteins directed against IL-1[beta] and/or IL-17
JP2016524611A (en) 2013-05-23 2016-08-18 ファイヴ プライム セラピューティクス インク How to treat cancer
KR20160042438A (en) 2013-08-12 2016-04-19 제넨테크, 인크. Compositions and method for treating complement-associated conditions
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
JP6422956B2 (en) 2013-10-11 2018-11-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Multispecific domain exchange common variable light chain antibody
PT3055331T (en) 2013-10-11 2021-04-05 Oxford Bio Therapeutics Ltd Conjugated antibodies against ly75 for the treatment of cancer
CA2928708A1 (en) 2013-10-25 2015-04-30 Acceleron Pharma, Inc. Endoglin peptides to treat fibrotic diseases
US10568951B2 (en) 2013-11-18 2020-02-25 Formycon Ag Pharmaceutical composition of an anti-VEGF antibody
EP3097122B9 (en) 2014-01-24 2020-11-11 NGM Biopharmaceuticals, Inc. Antibodies binding beta klotho domain 2 and methods of use thereof
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
CU24481B1 (en) 2014-03-14 2020-03-04 Immutep Sas ANTIBODY MOLECULES THAT JOIN LAG-3
JP2017516458A (en) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド Cancer treatment with c-met antagonist and correlation with HGF expression of c-met antagonist
EP3126386A1 (en) 2014-03-31 2017-02-08 F. Hoffmann-La Roche AG Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
US10179821B2 (en) 2014-05-01 2019-01-15 Genentech, Inc. Anti-factor D antibodies
US20170232199A1 (en) 2014-05-12 2017-08-17 Formycon Ag Pre-Filled Plastic Syringe Containing a VEGF Antagonist
EA037006B1 (en) 2014-06-06 2021-01-26 Бристол-Майерс Сквибб Компани Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
DK3180018T3 (en) 2014-08-12 2019-10-28 Massachusetts Inst Technology Synergistic tumor treatment with IL-2 and integrin-binding Fc fusion protein
US20170224777A1 (en) 2014-08-12 2017-08-10 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
JP6681905B2 (en) 2014-09-13 2020-04-15 ノバルティス アーゲー ALK inhibitor combination therapy
SG11201702606TA (en) 2014-10-03 2017-04-27 Massachusetts Inst Technology Antibodies that bind ebola glycoprotein and uses thereof
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
CR20170143A (en) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc ANTIBODY MOLECULES THAT JOIN PD-L1 AND USES OF THE SAME
EA201791029A1 (en) 2014-11-10 2017-12-29 Дженентек, Инк. ANTIBODIES AGAINST INTERLEUKIN-33 AND THEIR APPLICATION
ME03806B (en) 2014-11-21 2021-04-20 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
CA2971542A1 (en) 2014-12-19 2016-06-23 Regenesance B.V. Antibodies that bind human c6 and uses thereof
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
SG11201705063VA (en) 2014-12-23 2017-07-28 Bristol Myers Squibb Co Antibodies to tigit
EP3262216A4 (en) * 2015-02-24 2018-12-05 Academia Sinica A phage-displayed single-chain variable fragment library
EP3913052A1 (en) 2015-04-24 2021-11-24 F. Hoffmann-La Roche AG Methods of identifying bacteria comprising binding polypeptides
US9644032B2 (en) 2015-05-29 2017-05-09 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
MX2017015937A (en) 2015-06-08 2018-12-11 Genentech Inc Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists.
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
WO2017004016A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
PT3317301T (en) 2015-07-29 2021-07-09 Novartis Ag Combination therapies comprising antibody molecules to lag-3
JP6959912B2 (en) * 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド Optimized variant of anti-VEGF antibody
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
CA3001362C (en) 2015-10-30 2020-10-13 Genentech, Inc. Anti-htra1 antibodies and methods of use thereof
AU2016344133A1 (en) 2015-10-30 2018-05-17 Genentech, Inc. Anti-Factor D antibody formulations
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
SG11201803520PA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
CA3005117C (en) 2015-11-18 2023-01-24 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
CN108883057A (en) 2015-11-18 2018-11-23 Sio2医药产品公司 Drug packages for ophthalmology preparation
CA3005692A1 (en) 2015-11-18 2017-05-26 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
ES2926969T3 (en) 2015-11-19 2022-10-31 Bristol Myers Squibb Co Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and uses thereof
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
IL295230A (en) 2016-03-04 2022-10-01 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
WO2017151176A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
AU2017264578A1 (en) 2016-05-09 2019-01-03 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
TWI823836B (en) 2016-07-08 2023-12-01 美商建南德克公司 Use of human epididymis protein 4 (he4) for assessing responsiveness of cancer treatment
JP7050702B2 (en) 2016-07-08 2022-04-08 ジェネンテック， インコーポレイテッド Methods for diagnosing and treating cancer based on the expression status and mutation status of NRF2 and its downstream target gene
UY37325A (en) 2016-07-14 2018-01-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware MONOCLONAL ANTIBODIES THAT LINK TO TIM3 TO STIMULATE IMMUNE RESPONSES AND COMPOSITIONS CONTAINING THEM
JP2019524820A (en) 2016-08-12 2019-09-05 ジェネンテック， インコーポレイテッド Combination therapy with MEK inhibitor, PD-1 axis inhibitor and VEGF inhibitor
MY191894A (en) 2016-10-13 2022-07-18 Nat Univ Singapore Antibodies that bind zika virus envelope protein and uses thereof
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
EP3568150A4 (en) 2017-01-10 2020-12-02 Xcella Biosciences, Inc. Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
CA3055985A1 (en) * 2017-03-22 2018-09-27 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
TWI788340B (en) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
EP3630043A1 (en) 2017-05-24 2020-04-08 Formycon AG Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
US20200171244A1 (en) 2017-05-24 2020-06-04 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
SG11201912473PA (en) 2017-06-22 2020-01-30 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag Liquid formulation of a vegf antagonist
WO2019057946A1 (en) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag Multi-cyclic aromatic compounds as factor d inhibitors
JP7358361B2 (en) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Antibodies against TIM3 and their uses
CN111989095A (en) 2018-04-16 2020-11-24 上海岸阔医药科技有限公司 Method for preventing or treating side effects of tumor therapy
JP7361727B2 (en) 2018-05-24 2023-10-16 ヤンセン バイオテツク，インコーポレーテツド PSMA binder and its use
AR126019A1 (en) 2018-05-30 2023-09-06 Novartis Ag ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2020061210A1 (en) 2018-09-18 2020-03-26 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
WO2020102501A1 (en) 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
CA3131953A1 (en) 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
JP2022529985A (en) 2019-04-19 2022-06-27 ヤンセン バイオテツク，インコーポレーテツド How to treat prostate cancer with anti-PSMA / CD3 antibody
AU2020270376A1 (en) 2019-05-03 2021-10-07 Genentech, Inc. Methods of treating cancer with an anti-PD-L1 antibody
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US20230140384A1 (en) 2020-03-09 2023-05-04 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
IL296256A (en) 2020-03-13 2022-11-01 Genentech Inc Anti-interleukin-33 antibodies and uses thereof
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
EP4171617A1 (en) 2020-06-30 2023-05-03 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
KR20230135075A (en) 2021-01-22 2023-09-22 멘두스 비.브이. Tumor Vaccination Method
MX2023008909A (en) 2021-01-28 2023-10-23 Janssen Biotech Inc Psma binding proteins and uses thereof.
JP2024510989A (en) 2021-03-12 2024-03-12 メンドゥス・ベスローテン・フェンノートシャップ Vaccination methods and use of CD47 blockers
JPWO2023144973A1 (en) 2022-01-27 2023-08-03
CN118742325A (en) 2022-01-28 2024-10-01 上海岸阔医药科技有限公司 Methods for preventing or treating diseases or conditions associated with antineoplastic agents
WO2023155905A1 (en) 2022-02-21 2023-08-24 上海岸阔医药科技有限公司 Compound and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045450A1 (en) * 1996-05-31 1997-12-04 Health Research Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
US6416758B1 (en) * 1999-04-28 2002-07-09 Board Of Regents, The University Of Texax System Antibody conjugate kits for selectively inhibiting VEGF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045450A1 (en) * 1996-05-31 1997-12-04 Health Research Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
US6416758B1 (en) * 1999-04-28 2002-07-09 Board Of Regents, The University Of Texax System Antibody conjugate kits for selectively inhibiting VEGF

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BREKKEN ROLF A ET AL: "Vascular endothelial growth factor as a marker of tumor endothelium", CANCER RESEARCH, vol. 58, no. 9, 1 May 1998 (1998-05-01), pages 1952 - 1959, XP000918910, ISSN: 0008-5472 *
CHEN Y ET AL: "Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigen", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 293, no. 4, 5 November 1999 (1999-11-05), pages 865 - 881, XP004461879, ISSN: 0022-2836 *
KLOHS WAYNE D ET AL: "Antiangiogenic agents", CURRENT OPINION IN BIOTECHNOLOGY, vol. 10, no. 6, December 1999 (1999-12-01), pages 544 - 549, XP001206158, ISSN: 0958-1669 *
MORRISON KIM L ET AL: "Combinatorial alanine-scanning", CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 5, no. 3, June 2001 (2001-06-01), pages 302 - 307, XP002325957, ISSN: 1367-5931 *
POPKOV MIKHAIL ET AL: "Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: The impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display.", JOURNAL OF MOLECULAR BIOLOGY, vol. 325, no. 2, 10 January 2003 (2003-01-10), pages 325 - 335, XP002325954, ISSN: 0022-2836 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8674083B2 (en) 1999-01-15 2014-03-18 Genentech, Inc. Polypeptide variants with altered effector function
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
US9266948B2 (en) 2009-12-23 2016-02-23 Genentech, Inc. Anti-Bv8 antibodies and uses thereof
JP7227151B2 (en) 2017-03-22 2023-02-21 ジェネンテック， インコーポレイテッド Antibody Compositions Optimized for Treatment of Eye Disorders

Also Published As

Publication number Publication date
WO2005044853A2 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
WO2005044853A3 (en) Anti-vegf antibodies
WO2005012359A3 (en) Anti-vegf antibodies
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
WO2007056470A3 (en) Neuropilin antagonists
WO2006133088A3 (en) Improved human interferon molecules and their uses
EP1812065A4 (en) High affinity antibodies against hmgb1 and methods of use thereof
WO2006053301A3 (en) Fc variants with altered binding to fcrn
IL178593A0 (en) Fc??riib-specific antibodies and methods of use thereof
EA019476B9 (en) ANTI-IL-23p19 ANTIBODIES AND USE THEREOF
EP1587540A4 (en) IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
IL189263B (en) Identification and engineering of antibodies with variant fc regions and methods of using same
WO2008140493A3 (en) Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
WO2009097017A3 (en) Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
EP1668114A4 (en) Polypeptide display libraries and methods of making and using thereof
MY191348A (en) Antibodies and derivatives thereof
WO2006101387A3 (en) Method for interfering with blood coagulation by modulating cross-beta structures fibril formation
WO2008085987A3 (en) Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display
EA200801174A1 (en) GLP-2 MIMETIC ANTIBODIES, POLYPEPTIDES, COMPOSITIONS, METHODS AND APPLICATIONS
EP1742968A4 (en) Il-13 mutein proteins, antibodies, compositions, methods and uses
IL183400A0 (en) New peptides useful as dual caspase-2/-6 inhibitors and their biological applications
EP2631248A3 (en) Treatment of tumors using specific anti-L1 antibody
WO2006107813A3 (en) Site specific incorporation of phosphoserine into polypeptides using phosphoseryl-trna synthetase
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2004013290A3 (en) Compositions and methods for molecular biology
IL216656A0 (en) Identification and engineering of antibodies with variant fc regions and methods of using same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11414742

Country of ref document: US

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 11414742

Country of ref document: US